Fundraising FoxOrbiMed — 2026 Investments
10 investments dated 2026 · listed companies and verified rows first · show all
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalJanus Henderson InvestorsRA Capital+2 more
Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)inAnne-Renee Hartman(Founder)inAlan Williams(Executive Officer)inLisa Alderson(Executive Officer, Director)inPriscilla Huang(Executive Officer)in
Board seatDavid Bonita· per SEC Form D
Co-investorsDecheng CapitalF-Prime CapitalDeerfield Management CompanyMenlo Ventures
Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots.
BiotechHealthtechMedical DevicesKingston, US
Riyaz Bashir(Innovator / Creator of BASHIR Endovascular Catheters)John Cerminaro(Executive Officer)inMichael J. Cerminaro(Executive Officer, Director)inMarvin Woodall(Executive Officer, Director)Brian G. Firth(Executive Officer, Director)Todd Richmond(Director)
Board seatDavid Bonita· per SEC Form D
Co-investorsDelaware Crossing Investor Group
Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.
BiotechPalo Alto, US
James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)in
BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)Jill Carroll(Director)in
Co-investorsFrazier Life SciencesLongitude CapitalSR One Capital Management
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Co-investorsREDMILEVersant VenturesHBM Healthcare InvestmentsHBM PartnersBAM ElevateFranklin Templeton+5 more
Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.
Cloud ComputingEnterprise SoftwareFintechSaaS
Co-investorsCore Venture CapitalNycaNyca PartnersARCH Venture PartnersFidelity InvestmentsInvus+3 more
Nucleus RadioPharma develops and manufactures radiopharmaceutical products, with production facilities capable of scaling to hundreds of thousands of doses per year.
Advanced ManufacturingBiotechHealthtechPalo Alto, US
Stephen M. Hahn(Chief Executive Officer & Board Member)Tyrell Rivers(Director)Mary Kate Wold(Director)Michael Rossi(Director)Norman Sharpless(Director)Chris McDonald(Director)
Co-investorsEclipseEclipse Ventures
Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.
BiotechDigital HealthDoylestown, US
Chengzao Sun(Founder)inSandeep Somani(Founder)in
Co-investorsForesite CapitalQuan CapitalRA CapitalLAVVenrock
Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.
BiotechDeep TechSouth San Francisco, US
Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in
BoardMichael Goller(Director)Reid Huber(Director)inPeter Thompson(Director)in
Co-investorsEcoR1 CapitalRA CapitalNovo HoldingsThird Rock Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.